Breast Cancer Brain Metastasis Survival Data with Monocyte Ratios, 2008-2023

117 breast cancer patients who developed brain metastases from 2008 to 2023 were analyzed for changes in peripheral blood monocyte counts. The absolute monocyte count increased 2.11-fold at brain metastasis diagnosis, and a high lymphocyte-to-monocyte ratio was associated with a median survival of 20.0 months versus 5.13 months in the low group. This dataset, authored by Jihwan Yoo and shared under CC-BY-4.0, suggests monocyte dynamics may serve as exploratory prognostic markers.

Use Cases

• Predicting survival outcomes based on lymphocyte-to-monocyte ratio (LMR) values.
• Analyzing the association between platelet-to-monocyte ratio (PMR) and patient prognosis.
• Investigating the impact of triple-negative breast cancer subtype on survival in patients with brain metastases.
• Studying changes in absolute monocyte count (AMC) from primary to brain metastasis diagnosis.

Strengths

• Contains data from 117 patients with a defined study period from 2008 to 2023.
• Reports specific survival statistics, such as a 2.11-fold increase in absolute monocyte count and median survival differences (e.g., 20.0 vs. 5.13 months for LMR groups).
• Identifies specific prognostic factors like triple-negative subtype and number of brain metastases.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single retrospective study and may reflect inherent selection biases.

Provenance

Source

figshare

Collection Method

Retrospective study analyzing patient records and peripheral blood counts.

Time Range

2008 to 2023

Freshness

Last updated 2026-05-21 04:19:17; freshness should be verified.